Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development • Ophthalmology Pipeline Progress: The company continues to progress its lead candidates, SZN-8141 and SZN-8143 to address retinal diseases. The company remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026. • Patent Issuance: In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 by the U.S. Paten ...